ArticleScientific reports2025

Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study.

Xiaochun Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.